Double-Blind Clinical Trial of Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease
NCT ID: NCT06008717
Last Updated: 2024-12-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
40 participants
INTERVENTIONAL
2025-12-01
2029-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
active subthalamic nucleus deep brain stimulation plus optimal drug therapy
active subthalamic nucleus deep brain stimulation; plus optimal drug therapy
active subthalamic nucleus deep brain stimulation plus optimal drug therapy
active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy
inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
optimal drug therapy alone with DBS device turned off
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
active subthalamic nucleus deep brain stimulation plus optimal drug therapy
active subthalamic nucleus deep brain stimulation (DBS) plus optimal drug therapy
inactive subthalamic nucleus deep brain stimulation plus optimal drug therapy
optimal drug therapy alone with DBS device turned off
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clear and dramatic beneficial response to dopaminergic therapy, defined as ≥30% in UPDRS III with administration of the patient's medication during the screening neurological examination.
3. Hoehn and Yahr (H\&Y) stage II when OFF medication.
Exclusion Criteria
6. Dopaminergic therapy for greater than one year and less than four years.
7. Available for follow-up for the entire duration of the study.
8. Informed Consent (Appendix C): The subject is willing and able to provide written informed consent.
10. Subjects receiving antidepressant medication used specifically for the treatment of depression must be on stable doses for at least eight weeks prior to enrolling in the study.
11. Subjects must agree to maintain a stable regimen, if deemed medically appropriate by the treating physician, of any psychotropic medications throughout the blinded treatment phase.
1. Evidence of an alternative diagnosis or secondary parkinsonism, as suggested by:
* Features unusual early in the clinical course (e.g., prominent postural instability, freezing phenomena, or hallucinations unrelated to medications in the first 3 years after symptom onset)
* Dementia preceding motor symptoms
* Neurologic signs of upper motor neuron or cerebellar involvement
* Significant orthostatic hypotension unrelated to medications
* Unequivocal cortical sensory loss (i.e., graphesthesia, sterognosis with intact primary sensory modalities), clear limb ideomotor apraxia, or progressive aphasia
* Vertical supranuclear gaze palsy, or selective slowing of vertical saccades
* Unequivocal cerebellar abnormalities on examination, such as cerebellar gait, limb ataxia, or cerebellar oculomotor abnormalities (e.g., sustained gaze-evoked nystagmus, macro square wave jerks, hypermetric saccades)
* Documentation of a condition known to produce parkinsonism and plausibly connected to the subject's symptoms (e.g., MRI scan with evidence of significant brain atrophy, lacunar infarcts, or iron deposits in the putamen; history of stroke, exposure to toxins, or encephalitis; or neuroleptic use within the past 6 months)
* The expert evaluating physician, based on the full diagnostic assessment, believes that an alternative syndrome is more likely than PD.
2. Uncontrolled medical condition or clinically significant medical disease that would increase the risk of developing pre- or postoperative complications (e.g., significant cardiac or pulmonary disease, uncontrolled hypertension).
3. Dementia as evidenced by a Dementia Rating Score of less than 123.
4. Diagnosis of probable behavioral variant frontotemporal dementia or primary progressive aphasia.
5. Currently active diagnosis of a major psychiatric disorder.
6. Previous brain operation or injury.
7. Active participation in another clinical trial for the treatment of PD.
8. Subjects with cardiac pacemakers or medical conditions that require repeat MRI scans.
9. Evidence of existing dyskinesia
10. Any current substance use disorder.
11. Any history of recurrent or unprovoked seizures.
12. Any prior movement disorder treatments that involved intracranial surgery or device implantation.
13. Any other active implanted intracranial device (e.g., cochlear implant) or implanted device to treat movement disorders (e.g., duodopa pump) whether turned on or off.
14. A condition requiring or likely to require the use of magnetic resonance imaging (MRI) or diathermy.
15. History of suicide attempt.
16. A female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception.
17. Inability or unwillingness of subject to give written informed consent.
18. Parkinsonian features restricted to the lower limbs for more than three years.
19. Treatment with a dopamine receptor blocker or a dopamine-depleting agent in a dose and time course consistent with drug-induced parkinsonism.
20. Normal functional neuroimaging of the presynaptic dopaminergic system, as measured by DaTSCAN.
21. Rapid progression of gait impairment requiring regular use of a wheelchair.
22. Early bulbar dysfunction, defined as one of severe dysphonia, dysarthria (speech unintelligible most of the time), or dysphagia (requiring soft food, nasogastric (NG) tube, or gastrostomy feeding).
23. Inspiratory respiratory dysfunction defined as either diurnal or nocturnal inspiratory stridor or frequent inspiratory sighs.
24. Recurrent (\>1/year) falls because of impaired balance within 3 years of onset.
25. Otherwise unexplained pyramidal tract signs, defined as pyramidal weakness or clear pathologic hyperreflexia (excluding mild reflex asymmetry in the more affected limb and isolated extensor plantar response).
26. Bilateral symmetric parkinsonism throughout the disease course. The patient or caregiver reports bilateral symptom onset with no side predominance, and no side predominance is observed on objective examination.
50 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mallory Hacker
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mallory Hacker
Assistant Professor of Neurology
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
G220314
Identifier Type: -
Identifier Source: org_study_id